Table 3.
Risk factors of the cohort study, data in %, unless otherwise stated.
| Parameter | Total procedures (n = 128) | No CIN (n = 122) | CIN (n = 6) | P value |
|---|---|---|---|---|
| Age (years) | 74.3 ± 8.8 | 74.3 ± 8.9 | 75.8 ± 8.1 | 0.58 |
| Sex (women) | 47% (60/128) | 48% (58/122) | 33% (2/6) | 0.50 |
| Contrast medium dose (mL) | 80.8 ± 50.4 | 81.3 ± 50.7 | 71.7 ± 47.2 | 0.78 |
| Body height* (m) | 1.70 ± 0.10 | 1.70 ± 0.10 | 1.68 ± 0.15 | 0.91 |
| weight (kg) | 75.6 ± 16.8 | 75.5 ± 17.2 | 76.7 ± 8.1 | 0.60 |
| Contrast administrations (n) | 1.23 ± 0.60 | 1.25 ± 0.61 | 1 | 0.25 |
| Repeated contrast administrations <21 days | 13% (16/128) | 13% (16/122) | 0% (0/6) | 0.34 |
| BMI*† (kg/m2) | 26.6 ± 5.0 | 26.5 ± 5.0 | 27.4 ± 6.0 | 0.97 |
| baseline eGFR (mL/min/1.73m2) | 45.3 ± 10.5 | 45.6 ± 10.4 | 38.5 ± 12.4 | 0.10 |
| SCr before therapy (μmol/L) | 136 ± 61 | 134 ± 60 | 171 ± 75 | 0.06 |
| Volume of isotonic saline (NaCl 0.9%) iv (mL) | 1199 ± 749 | 1200 ± 749 | 1167 ± 816 | 0.96 |
| Arterial hypertension | 86% (110/128) | 86% (105/122) | 83% (5/6) | 0.85 |
| Type 2 diabetes mellitus | 43% (55/128) | 44% (54/122) | 17% (1/6) | 0.18 |
| Coronary heart disease | 50% (64/128) | 50% (61/122) | 50% (3/6) | >0.99 |
| Congestive heart failure | 29% (37/128) | 28% (34/122) | 50% (3/6) | 0.24 |
| Cerebrovascular disease | 34% (44/128) | 35% (42/122) | 33% (2/6) | 0.96 |
| AT1-antagonist | 20% (25/128) | 19% (23/122) | 33% (2/6) | 0.38 |
| Ca2+-antagonist | 26% (33/128) | 26% (32/122) | 17% (1/6) | 0.61 |
| Diuretics | 58% (74/128) | 57% (69/122) | 83% (5/6) | 0.20 |
| Non-steroidal anti-inflammatory drugs | 70% (90/128) | 71% (86/122) | 67% (4/6) | 0.84 |
| Paracetamol | 2% (3/128) | 3% (3/122) | 0% (0/6) | 0.70 |
| Total number of risk factors | 6.3 ± 2.0 | 7.0 ± 1.5 | 6.3 ± 1.5 | 0.982 |
Average value ± standard deviation.
Numbers in parentheses are absolute number of cases.
*
Body height and BMI could be determined in only 94 cases.
†Body mass index = body weight [kg] / (body height [m])2.